These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38215770)

  • 61. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial.
    de Wijkerslooth EML; Boerma EG; van Rossem CC; van Rosmalen J; Baeten CIM; Beverdam FH; Bosmans JWAM; Consten ECJ; Dekker JWT; Emous M; van Geloven AAW; Gijsen AF; Heijnen LA; Jairam AP; Melles DC; van der Ploeg APT; Steenvoorde P; Toorenvliet BR; Vermaas M; Wiering B; Wijnhoven BPL; van den Boom AL;
    Lancet; 2023 Feb; 401(10374):366-376. PubMed ID: 36669519
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort.
    Palacios-Baena ZR; Delgado-Valverde M; Valiente Méndez A; Almirante B; Gómez-Zorrilla S; Borrell N; Corzo JE; Gurguí M; De la Calle C; García-Álvarez L; Ramos L; Gozalo M; Morosini MI; Molina J; Causse M; Pascual Á; Rodríguez-Baño J;
    Clin Infect Dis; 2019 Aug; 69(6):956-962. PubMed ID: 30535051
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.
    Paul M; Bishara J; Yahav D; Goldberg E; Neuberger A; Ghanem-Zoubi N; Dickstein Y; Nseir W; Dan M; Leibovici L
    BMJ; 2015 May; 350():h2219. PubMed ID: 25977146
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia: the INTENSE trial protocol.
    Maldonado N; Rosso-Fernández CM; Portillo-Calderón I; Borreguero Borreguero I; Tristán-Clavijo E; Palacios-Baena ZR; Salamanca E; Fernández-Cuenca F; De-Cueto M; Stolz-Larrieu E; Rodriguez-Baño J; López-Cortés LE
    BMJ Open; 2023 Sep; 13(9):e075699. PubMed ID: 37673453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial.
    Westendorp WF; Vermeij JD; Zock E; Hooijenga IJ; Kruyt ND; Bosboom HJ; Kwa VI; Weisfelt M; Remmers MJ; ten Houten R; Schreuder AH; Vermeer SE; van Dijk EJ; Dippel DW; Dijkgraaf MG; Spanjaard L; Vermeulen M; van der Poll T; Prins JM; Vermeij FH; Roos YB; Kleyweg RP; Kerkhoff H; Brouwer MC; Zwinderman AH; van de Beek D; Nederkoorn PJ;
    Lancet; 2015 Apr; 385(9977):1519-26. PubMed ID: 25612858
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
    Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
    Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant
    Marín-Candón A; Rosso-Fernández CM; Bustos de Godoy N; López-Cerero L; Gutiérrez-Gutiérrez B; López-Cortés LE; Barrera Pulido L; Borreguero Borreguero I; León MJ; Merino V; Camean-Fernández M; Retamar P; Salamanca E; Pascual A; Rodriguez-Baño J;
    BMJ Open; 2021 Sep; 11(9):e049481. PubMed ID: 34580096
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
    Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
    Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia.
    Lee CC; Wang JL; Lee CH; Hung YP; Hong MY; Tang HJ; Ko WC
    Int J Antimicrob Agents; 2017 Sep; 50(3):371-376. PubMed ID: 28694235
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
    Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
    Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Moniche F; Cabezas-Rodriguez JA; Valverde R; Escudero-Martinez I; Lebrato-Hernandez L; Pardo-Galiana B; Ainz L; Medina-Rodriguez M; de la Torre J; Escamilla-Gomez V; Ortega-Quintanilla J; Zapata-Arriaza E; de Albóniga-Chindurza A; Mancha F; Gamero MA; Perez S; Espinosa-Rosso R; Forero-Diaz L; Moya M; Piñero P; Calderón-Cabrera C; Nogueras S; Jimenez R; Martin V; Delgado F; Ochoa-Sepúlveda JJ; Quijano B; Mata R; Santos-González M; Carmona-Sanchez G; Herrera C; Gonzalez A; Montaner J
    Lancet Neurol; 2023 Feb; 22(2):137-146. PubMed ID: 36681446
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis.
    Furno P; Dionisi MS; Bucaneve G; Menichetti F; Del Favero A
    Support Care Cancer; 2000 Jul; 8(4):293-301. PubMed ID: 10923769
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.